>RGD containing collagen associated protein; AI181842; AI747162; Beta ig; Beta ig h3; Beta ig-h3; BGH3; Big h3; BIGH3; CDB1; CDG2; CDGG1; CSD; CSD1; CSD2; CSD3; EBMD; Kerato epithelin; Kerato-epithelin; LCD1; MGC150270; RGD CAP; RGD-CAP; RGD-containing collagen-associated protein; TGFBI; TGFBI transforming growth factor; beta induced; 68kDa; Transforming growth factor beta induced protein ig h3; Transforming growth factor-beta-induced protein ig-h3

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG2a

654

Mouse

Caprylic acid/ammonium sulfate precipitation

1mg/mL (lot specific)

Store at -20 degree C. Avoid freeze / thaw cycles.

Manufactured in an ISO 9001:2015 Certified Laboratory.

Small volumes of anti-TGFBI antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

TGFBI, also named as BIGH3, Kerato-epithelin and RGD-CAP, binds to type I, II, and IV collagens. TGFBI is an adhesion protein which may play an important role in cell-collagen interactions. In cartilage, it may be involved in endochondral bone formation. TGFBI is an extracellular matrix adaptor protein, it has been reported to be differentially expressed in transformed tissues. TGFBI is a predictive factor of the response to chemotherapy, and suggest the use of TGFBI-derived peptides as possible therapeutic adjuvants for the enhancement of responses to chemotherapy. Defects in TGFBI are the cause of epithelial basement membrane corneal dystrophy (EBMD). Defects in TGFBI are the cause of corneal dystrophy Groenouw type 1 (CDGG1). Defects in TGFBI are the cause of corneal dystrophy lattice type 1 (CDL1). Defects in TGFBI are a cause of corneal dystrophy Thiel-Behnke type (CDTB). Defects in TGFBI are the cause of Reis-Buecklers corneal dystrophy (CDRB). Defects in TGFBI are the cause of lattice corneal dystrophy type 3A (CDL3A). Defects in TGFBI are the cause of Avellino corneal dystrophy (ACD).

Cancer; Developmental biology; Neuroscience; Signal transduction

Western Blot (WB), Immunohistochemistry (IHC), ELISA (EIA)

WB: 1:200-1:2000
IHC: 1:20-1:200

Western Blot analysis of extracellularmedia LEC grown for 24 h under normoxia (N), hypoxia (H) or hypoxia and reoxygenation (H/N) for 6 h with TGFBI / BIGH3 Monoclonal Antibody . Silver staining of the membranes was used as loading control.

Calculated: 75kDa
Observed: 68kDa

transforming growth factor beta induced

transforming growth factor-beta-induced protein ig-h3

Transforming growth factor-beta-induced protein ig-h3

BIGH3; Beta ig-h3; RGD-CAP??[Similar Products]

This gene encodes an RGD-containing protein that binds to type I, II and IV collagens. The RGD motif is found in many extracellular matrix proteins modulating cell adhesion and serves as a ligand recognition sequence for several integrins. This protein plays a role in cell-collagen interactions and may be involved in endochondrial bone formation in cartilage. The protein is induced by transforming growth factor-beta and acts to inhibit cell adhesion. Mutations in this gene are associated with multiple types of corneal dystrophy. [provided by RefSeq, Jul 2008]

Plays a role in cell adhesion (PubMed:8024701). May play a role in cell-collagen interactions ().

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.